Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 3: 568 - 573

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230227.001

Effects of Traditional Chinese Medicine on the survival of patients with stage I gastric cancer and high-risk factors: a real-world retrospective study

  • Chao HOU ,
  • Yusen ZHANG ,
  • Die YANG ,
  • Yifei LI ,
  • Xiaochun ZHANG ,
  • Yanqing LIU
Expand
  • 1 Department of Oncology and Hematology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China
    2 College of Medicine, Yangzhou University, Yangzhou 225001, China
    3 the Key Laboratory of Syndrome Differentiation and Treatment of Gastric Cancer of the State Administration of Traditional Chinese Medicine, Yangzhou 225001, China
    4 Oncology Department, Yangzhou Hospital of Traditional Chinese Medicine, Yangzhou 225009, China

Received date: 2022-02-02

  Accepted date: 2022-06-08

  Online published: 2023-02-27

Supported by

Efficacy Evaluation and Proteomics Study of Jianpi Yangzheng Xiaozheng Recipe on the Stage Ⅲ and Ⅳ Gastric Cancer Based on Real-world Evidence(137070586)

Fold

Abstract

OBJECTIVE: To investigate the benefits of Traditional Chinese Medicine (TCM) therapy for improving the survival of patients with stage I gastric cancer (GC) and high-risk factors in a real-world setting.

METHODS: The clinical data of patients who were diagnosed with stage I GC from March 1, 2012 to October 31, 2020 were collected. Prognostic analysis was performed to explore the high-risk factors that affected the survival of the patients. A Cox multivariate regression model was used to compare the hazard ratios for the mortality risk of patients, especially those with high-risk factors. Kaplan-Meier survival curve and log-rank test were utilized to assess the survival time.

RESULTS: Prognostic analysis demonstrated that female sex, tumor invasion into blood vessels, and Ib stage were independent risk factors. The 1-, 3-, and 5-year survival rates of the TCM group vs those of the non-TCM group were 100.0% vs 91.0%, 97.6% vs 64.5%, and 81.4% vs 55.5%, respectively. A significant difference in median overall survival (mOS) was found between the two groups (χ2 = 7.670, P = 0.006). Subgroup analysis showed that the mOS of female patients and stage Ib patients in the TCM group were longer than those in the non-TCM group (P ≤ 0.001 and 0.001, respectively).

CONCLUSIONS: TCM treatment can improve the survival of patients with stage I GC and high-risk factors.

Key words： stomach neoplasms; overall mortality; integrative medicine; medicine, Chinese traditional; real-world

Cite this article

Chao HOU , Yusen ZHANG , Die YANG , Yifei LI , Xiaochun ZHANG , Yanqing LIU . Effects of Traditional Chinese Medicine on the survival of patients with stage I gastric cancer and high-risk factors: a real-world retrospective study[J]. Journal of Traditional Chinese Medicine, 2023 , 43(3) : 568 -573 . DOI: 10.19852/j.cnki.jtcm.20230227.001

References

[1] Thrift A, El-Serag H. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020; 18: 534-42.
[2] Liu ZC, Li ZX, Zhang Y, et al. Interpretation on the report of global cancer statistics 2020. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi 2021; 7: 1-13.
[3] Ajani J, D'Amico T, Almhanna K, et al. Gastric cancer, version 3. 2016, NCCN clinical practice guidelines in oncology. JNCCN 2016; 14: 1286-312.
[4] Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999; 354: 273-77.
[5] Seyedin S, Wang P, Zhang Q, Lee P. Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: a seer population analysis. Gastrointest Cancer Res 2014; 7: 82-90.
[6] Du C, Zhou Y, Huang K, Zhao G, Fu H, Shi Y. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg 2011; 15: 2153-8.
[7] Jin L, Moses L, Squires M, et al. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: a 7-institution study of the US gastric cancer collaborative. Ann Surg 2015; 262: 999-1005.
[8] Wang Z, Yan J, Hu W, Zhang J, Huo B. Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors. Neoplasma 2018; 65: 592-8.
[9] Hung K, Hsu C, Chiang J, et al. Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study. J Ethnopharmacol 2017; 199: 168-74.
[10] Liao Y, Li C, Lin C, Lin J, Chiang J, Li T. Traditional Chinese Medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017; 143: 2425-35.
[11] Zhai X, Liu X, Shen F, Fan J, Ling C. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study. Cancer 2018; 124: 2161-8.
[12] Liu X, Xiu L, Jiao J, et al. Traditional Chinese Medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis. J Integr Med 2017; 15: 469-75.
[13] Wu JR, Zhang D, Ni MW, et al. Effectiveness of Huachansu injection combined with chemotherapy for treatment of gastric cancer in China: a systematic review and Meta-analysis. J Tradit Chin Med 2020; 40: 749-57.
[14] Sun X, Tan J, Tang L, Guo J, Li X. Real world evidence: experience and lessons from China. BMJ 2018; 4: 1-4.
[15] Shih W, Yang P, Shen Y, Yang Y, Wu C. Traditional Chinese Medicine enhances survival in patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: a nationwide matched cohort study. Evid-based Complement Altern Med 2021; 2021: 1-8.
[16] Chen Y, Zhang G, Chen X, et al. Jianpi Bushen, a Traditional Chinese Medicine therapy, combined with chemotherapy for gastric cancer treatment: a Meta-analysis of randomized controlled trials. Evid-based Complement Altern Med 2018; 2018: 1-14.
[17] Zhang R, Ma C, Wei Y, et al. Isolation, purification, structural characteristics, pharmacological activities, and combined action of Hedyotis Diffusa polysaccharides: a review. Int J Biol Macromol 2021; 183: 119-31.
[18] Zhang D, Wu J, Wang K, Duan X, Liu S, Zhang B. Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer? a PRISMA-compliant network Meta-analysis. Medicine 2018; 97: 12.
[19] Fang T, Li J, Wu X. Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis. Drug Dev Res 2018; 79: 324-31.
[20] Zhang Y, Zhang M, Jiang Y, et al. Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China. J Cancer Res Clin Oncol 2018; 144: 2177-86.
[21] Wang JC, Long G, Ye Z, et al. Effect of Aidi injection plus chemotherapy on gastric carcinoma: a Meta-analysis of randomized controlled trials. J Tradit Chin Med 2015; 35: 361-74.
Options
Outlines

/

〈 〉